Valuation : TScan Therapeutics, Inc.

Market Cap 50.85M 43.65M 40.86M 37.42M 70.49M 4.86B 70.69M 484M 189M 2.45B 191M 187M 8.1B P/E 2026 *
-0.83x
P/E 2027 * -0.77x
Enterprise Value -48.02M -41.22M -38.59M -35.34M -66.57M -4.59B -66.76M -457M -179M -2.31B -180M -176M -7.65B EV / Sales 2026 *
-7.76x
EV / Sales 2027 * -3.67x
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -
08-18 TScan Therapeutics, Inc. And Amgen Inc. Terminate Research Collaboration And License Agreement CI
08-12 TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-29 Tscan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial Evaluating TSC-101 in Patients with Heme Malignancies CI
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-26 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-18 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-06 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
1 day+2.37%
1 week-3.35%
Current month+0.97%
1 month-2.36%
3 months-29.89%
6 months-29.23%
Current year-24.98%
1 week 0.75
Extreme 0.7474
0.81
1 month 0.72
Extreme 0.716
0.84
Current year 0.72
Extreme 0.716
1.47
1 year 0.72
Extreme 0.716
2.57
3 years 0.72
Extreme 0.716
9.69
5 years 0.72
Extreme 0.716
9.69
10 years 0.72
Extreme 0.716
14.71
Manager TitleAgeSince
Chief Executive Officer 56 27/03/2023
Director of Finance/CFO 57 28/01/2024
Chief Tech/Sci/R&D Officer 50 07/04/2024
Director TitleAgeSince
Director/Board Member 68 22/03/2021
Director/Board Member 56 23/05/2023
Chairman 55 11/06/2024
Date Insider Type Main position Quantity % Market Cap.
20/05/26 Free

Director

67,000 0.1200%
20/05/26 Free

Director

67,000 0.1200%
20/05/26 Free

Director

67,000 0.1200%
Change 5-day change 1-year change 3-year change Capi.($)
+2.37%-3.35%-59.88%-66.21% 50.85M
+3.31%-3.70%+61.03%+103.64% 70.64B
-0.57%-0.11%+49.52%+91.87% 66.11B
-8.92%+0.46%+8.14%-5.28% 27.98B
-0.99%-2.95%-9.77%+455.82% 26.51B
+0.30%-0.69%+63.18%+11.93% 26.44B
+1.02%+6.43%+269.42%+420.34% 20.4B
-0.18%+0.70%+34.33%-17.64% 20.17B
-1.91%-4.37%+13.33%+531.29% 15.99B
-0.80%+2.92%+43.50%+151.30% 13.69B
Average -0.74%+0.55%+47.28%+167.70% 28.8B
Weighted average by Cap. -0.45%+0.65%+56.32%+154.28%

Financials

2026 *2027 *
Net sales 6.19M 5.31M 4.97M 4.55M 8.58M 591M 8.6M 58.89M 23.02M 298M 23.23M 22.73M 986M 6.51M 5.59M 5.23M 4.79M 9.03M 622M 9.05M 61.97M 24.22M 313M 24.45M 23.92M 1.04B
Net income -119M -102M -95.46M -87.41M -165M -11.34B -165M -1.13B -442M -5.72B -446M -436M -18.92B -131M -112M -105M -96.13M -181M -12.48B -182M -1.24B -486M -6.29B -490M -480M -20.81B
Net Debt -98.87M -84.87M -79.45M -72.76M -137M -9.44B -137M -941M -368M -4.76B -371M -363M -15.75B -74.76M -64.17M -60.08M -55.01M -104M -7.14B -104M -711M -278M -3.6B -281M -275M -11.91B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
138
Date Price Change Volume
27/08/26 US$0.7502 -3.50% 288,103
26/08/26 US$0.7774 -2.05% 68,396
25/08/26 US$0.7937 -0.70% 180,597
24/08/26 US$0.7993 +2.54% 194,411
21/08/26 US$0.7795 +0.43% 136,157
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.7502USD
Average target price
6.000USD
Spread / Average Target
+699.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock